Genmab Announces Multiple Myeloma Antibody Program
Genmab A/S announced its new HuMax®-CD38 program for the treatment of multiple myeloma. HuMax-CD38 is a human IgG1,k antibody selected from a large panel of antibodies based on its ability to bind and to kill multiple myeloma tumor cells. The HuMax-CD38 antibody targets the CD38 molecule which is very highly expressed on the surface of multiple myeloma cells.
In preclinical studies, HuMax-CD38 was effective in killing primary multiple myeloma tumor cells and a range of tumor cell lines by triggering two immune system killing mechanisms: Antibody-Dependent Cellular Cytotoxicity (ADCC) and Complement Dependent Cytotoxicity (CDC). In animal models using sensitive bioluminescence imaging, treatment with HuMax-CD38 slowed tumor growth in both preventive and therapeutic settings in SCID mice. These are mice with a deficient immune system, in which human tumor cells can grow.
Multiple myeloma is a cancer of plasma cells and accounts for approximately 1% of all cancers. The incidence of multiple myeloma is 5.2 per 100,000 people corresponding to 15,270 new cases in the US in 2004. In the US, approximately 11,000 deaths each year are related to multiple myeloma. At present, no cure is available, and the mean survival is approximately 3 years from time of diagnosis.
Topics
Organizations
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents

Researchers discover new fat-fighting pathway

Crucial step identified in the conversion of biomass to methane - Researchers find the enzymatic link in the formation of methane from fatty acids by cooperating microorganisms

'Squirtable' elastic surgical glue seals wounds in 60 seconds

Sustainable scents from the mountain of the gods - ETH Zurich chemist Michailidou could see herself founding her own start-up: “That would be a dream come true”
ORVACS Phase II clinical study attacks the viral reservoir of HIV patients
Ambion to Provide MitoCheck Consortium a Genome-Wide siRNA Library
A pentavalent inhibitor for cholera toxin
Affimed joins the Molecular Imaging Technology Initiative - BMBF awards Affimed a funding grant of €550K
Novartis awards 2010 Prizes for Immunology in recognition of outstanding contributions to immunology in medical research

Revolutionary Breakthrough: A Drug Slows Down Leukaemia Progression by Blocking Cancer-Causing Genes - Scientists demonstrate the therapeutic value of a compound that inhibits oncogene translation

In slow motion against antibiotic resistance - How novel therapeutics provide insight into bacteria membranes
